Product Detail
rac-5-Hydroxymethyl Tolterodine Methacrylate-d14
Stable Isotopes
Stock Status: Enquire
Live
For Research & Analytical Purposes. Not for Personal use.
Category
Stable Isotopes
API Family
--
Storage
Refer MSDS for complete information.
Hazard Information
Refer MSDS for complete information.
rac-5-Hydroxymethyl Tolterodine Methacrylate-d14 Product Information
rac-5-Hydroxymethyl Tolterodine Methacrylate-d14 is listed under Stable Isotopes. It is associated with and is intended for analytical research, quality control and pharmaceutical reference standard applications. The product is supplied by Clearsynth under CAT No. CS-T-101042.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight, stock enquiry details and supporting documentation.
Technical Data
Product Name
rac-5-Hydroxymethyl Tolterodine Methacrylate-d14
CAS No.
-
CAT No.
CS-T-101042
Molecular Formula
C26H21D14NO3
Molecular Weight
423.65
Category
Storage Condition
Refer MSDS for complete information.
IUPAC Name
rac-5-Hydroxymethyl Tolterodine Methacrylate-d14
Hazard Compound
Refer MSDS for complete information.
Description
Overview
"rac-5-Hydroxymethyl Tolterodine Methacrylate-d14 is the isotope labelled analog of rac-5-Hydroxymethyl Tolterodine Methacrylate. ac-5-Hydroxymethyl Tolterodine Methacrylate-d14 is a metabolite of Tolterodine (T535800), a muscarinic receptor antagonist used in the treatment of urinary incontinence. Also, a degradation product of Fesoterodine (F321300) formed under stress conditions in tablet dosage forms."
Synonyms
rac-5-Hydroxymethyl Tolterodine Methacrylate-d14
Application Notes
"rac-5-Hydroxymethyl Tolterodine Methacrylate-d14 is the isotope labelled analog of rac-5-Hydroxymethyl Tolterodine Methacrylate. ac-5-Hydroxymethyl Tolterodine Methacrylate-d14 is a metabolite of Tolterodine (T535800), a muscarinic receptor antagonist used in the treatment of urinary incontinence. Also, a degradation product of Fesoterodine (F321300) formed under stress conditions in tablet dosage forms."
References
"Palmer, L., et al.: J. Pharm. Biomed. Anal., 16, 155 (1997), Hills, C., et al.: Drugs, 55, 813 (1998), Wefer, J., et al.: World J. Urol., 19, 312 (2001),"
![D-[4,4'-D2]erythrose chemical structure](https://structures.clearsynth.com/CS-OC-00089.PNG)
